highthroughput
screen
ht
repres
domin
techniqu
identif
new
lead
compound
current
drug
discoveri
consist
physic
screen
ps
larg
librari
chemic
one
specif
biolog
target
virtual
screen
vs
strategi
silico
evalu
chemic
librari
given
target
integr
focu
ps
process
present
work
address
integr
ps
vs
respect
section
editor
random
physic
screen
ps
compound
collect
inhous
databas
pharmaceut
compani
catalog
variou
chemic
vendor
repres
longrang
strategi
regard
substitut
serendip
autom
compound
handl
assay
facil
current
enabl
task
compound
retriev
storag
dilut
plate
sampl
therefor
ps
reach
potenti
identifi
hit
time
basi
random
screen
enabl
success
fulfil
initi
expect
gross
increas
number
assay
compound
guarante
better
product
per
se
also
ps
result
free
error
differ
assay
format
target
give
differ
result
silico
screen
virtual
librari
compound
conceptu
econom
attract
make
possibl
evalu
almost
unlimit
number
chemic
structur
subset
select
subsequ
assay
ps
experi
typic
virtual
screen
vs
method
involv
exampl
filter
librari
compound
contain
toxic
reactiv
otherwis
undesir
group
contrast
search
molecul
prefer
leador
druglik
properti
desir
activ
fact
vs
emerg
key
strategi
help
filter
compound
poor
potenc
biolog
pharmacolog
properti
recent
review
suggest
vs
often
present
altern
ps
strategi
highli
complementari
current
trend
pharmaceut
industri
integr
comput
experiment
technolog
earli
drug
discoveri
process
instanc
consid
better
earlier
util
inform
genom
ii
chemic
iii
biolog
iv
structur
v
molecular
properti
data
would
lead
chemic
librari
desir
chemic
biolog
properti
done
integr
inform
differ
area
includ
analysi
gene
protein
famili
target
select
ii
absorpt
distribut
metabol
excret
toxic
evalu
adm
tox
iii
structur
biolog
iv
vs
v
medicin
chemistri
parallel
synthesi
fig
literatur
report
show
increas
depend
integr
vs
ps
identifi
lead
drug
discoveri
process
twentythre
repres
studi
summar
tabl
list
target
studi
ii
strategi
appli
vs
ps
method
iii
size
librari
evalu
iv
result
achiev
project
last
column
indic
origin
refer
tabl
reveal
vs
workflow
use
studi
preliminari
filter
virtual
librari
ten
hundr
thousand
compound
use
variou
criteria
eg
lipinski
rule
five
ii
homolog
pharmacophor
model
combin
iii
dock
score
proteinligand
complex
ps
method
assay
particular
specif
target
appli
base
fluoresc
detect
outcom
studi
indic
preliminari
vs
drastic
reduc
number
chemic
physic
screen
also
increas
hit
rate
vs
knowledgedriven
approach
depend
amount
qualiti
inform
avail
system
investig
know
structur
biolog
target
macromolecul
offer
mani
advantag
comparison
situat
inform
geometri
bioactiv
refer
ligand
avail
structur
inform
target
avail
either
fact
infer
consid
targetbas
structurebas
virtual
screen
tbv
case
repres
ligandbas
virtual
screen
lbv
refer
compound
known
substrat
inhibitor
agonist
antagonist
among
other
import
issu
target
select
druggabl
molecul
consider
whether
target
amen
therapeut
intervent
via
small
molecul
one
approach
assess
whether
member
gene
famili
show
similar
bind
affin
toward
druglik
ligand
relat
physicochem
properti
approach
sometim
refer
target
fish
see
j
l
jenkin
issu
advent
structur
genom
homolog
model
initi
number
potenti
target
expect
grow
instanc
last
year
new
target
screen
nih
molecular
librari
initi
formerli
molecular
librari
screen
center
network
http
mlinihgov
expect
screen
within
next
year
center
new
mexico
molecular
librari
screen
center
http
screeninghealthunmedu
undertaken
project
sever
class
receptor
includ
two
gpcr
list
tabl
integrin
formyl
peptid
receptor
compar
sever
strategi
includ
screen
classfocus
gpcr
targetfocus
fpr
librari
tabl
latter
case
use
homolog
model
pharmacophor
dock
select
compound
librari
record
activ
molecul
rate
prestwick
chemic
librari
http
wwwprestwickchemicalcomchemlibhtm
divers
set
nih
small
molecul
repositori
http
mlsmrglpgcom
mlsmrhomepag
gpcr
class
focus
librari
chemdiv
http
wwwchemdivcomenproductsscreen
target
focus
librari
case
targetspecif
ligand
known
perform
lbv
latter
two
librari
use
refer
ligand
rank
top
structur
ps
find
one
select
nm
affin
agonist
two
eraerb
bind
cg
bologa
unpublish
gener
workflow
shown
fig
current
implement
new
mexico
molecular
librari
screen
center
follow
gener
templat
present
fig
core
system
repres
screen
databas
complet
inform
relat
chemic
structur
data
compound
exist
inhous
purchas
differ
vendor
ii
bioactiv
data
plate
format
inform
biolog
screen
outcom
record
workflow
step
well
defin
biolog
team
provid
target
correspond
assay
screen
team
respons
ps
compound
regist
databas
cheminformat
team
plate
creat
record
databas
medicin
chemistri
team
provid
chemistri
followup
properti
optim
continu
inform
exchang
screen
cheminformat
medicin
chemistri
team
base
outcom
screen
team
cheminformat
team
appli
vs
posthighthroughput
screen
ht
analys
identifi
priorit
compound
chemotyp
evalu
medicin
chemistri
team
verifi
chemic
qualit
chemistri
qc
propos
hit
give
feedback
screen
cheminformat
team
final
result
repres
socal
chemic
probe
inhibitor
activ
modul
studi
target
vs
method
comprehens
review
see
muegg
issu
therefor
brief
descript
given
vs
workflow
shown
fig
two
main
type
vs
target
structurebas
virtual
screen
tbv
sbv
ii
lbv
tbv
appli
target
protein
enzym
structur
known
base
crystallograph
structur
method
ii
built
use
homolog
model
procedur
consist
dock
larg
number
molecul
activ
site
target
score
bind
affin
limit
step
strategi
accur
score
four
categori
score
function
knowledgebas
method
none
scheme
shown
gener
prefer
use
consensusscor
method
lbv
method
start
known
bioactiv
inhibitor
activ
similar
search
classif
method
use
select
novel
scaffold
see
k
v
balakin
issu
filter
appli
forward
ii
backward
hit
obtain
vs
campaign
forward
filter
select
criteria
use
reduc
size
initi
librari
sever
million
sever
hundr
hundr
test
compound
dock
backward
procedur
use
filter
criteria
priorit
candid
ps
postht
analysi
test
strategi
select
compound
includ
doesrespons
character
cytotox
select
compound
center
mani
assay
set
high
throughput
multiplex
select
specif
inform
famili
target
avail
individu
compound
physic
properti
compon
test
contribut
screen
strategi
presenc
molecul
insolubl
aggreg
fluoresc
interfer
identif
activ
assay
screen
compound
librari
paramount
assay
optim
complexitysimpl
minim
addit
wash
step
simpl
detect
scheme
volum
typic
ml
permit
use
well
plate
reproduc
librari
screen
twice
howev
vs
technolog
reduc
librari
size
compound
mani
constraint
lift
allow
use
physiolog
relev
complex
assay
potenti
includ
whole
animalbas
assay
recogn
viabl
altern
today
search
novel
pharmaceut
anoth
issu
relat
assay
implement
select
vitro
vs
vivo
assay
mani
initi
hit
enzymeproteinbas
vitro
assay
may
fail
cellular
anim
level
due
stabil
metabol
issu
howev
develop
vs
postht
analysi
method
minim
final
assay
select
strong
influenc
outcom
physic
screen
exampl
use
simpl
bind
assay
screen
yield
agonist
antagonist
target
activ
agonist
desir
function
assay
base
target
activ
might
preferenti
select
result
vs
ps
yield
larg
number
often
order
interest
hit
warrant
attent
issu
molecul
select
doserespons
confirm
often
left
medicin
chemist
biologist
requir
cheminformat
support
center
appli
follow
postht
priorit
scheme
chemotyp
well
individu
molecul
evalu
see
box
thu
postht
analysi
essenti
practic
step
design
assist
decisionmak
evalu
compound
experi
appli
confirm
hit
structur
puriti
well
doserespons
level
final
score
captur
inform
relat
activ
also
inact
chemic
famili
intellectu
properti
toxic
evalu
scheme
aim
encod
inform
relat
individu
chemotyp
individu
molecul
level
use
estim
physicochem
properti
assist
final
priorit
score
integr
vs
ps
technolog
attract
scientif
econom
reason
scientif
one
reduc
search
space
rapidli
find
solut
econom
one
longer
requir
screen
million
compound
physic
identifi
hit
neg
aspect
integr
effort
theoret
practic
natur
theoret
streamlin
ps
may
result
test
wrong
librari
subset
relat
limit
theoret
method
inappropri
use
vs
technolog
practic
speak
possibl
entir
effort
lead
naught
case
doubt
typic
cast
silico
approach
although
experiment
techniqu
without
flaw
either
continu
inform
exchang
effect
team
commun
illustr
fig
avoid
neg
situat
integr
technolog
support
increas
amount
valuabl
inform
deposit
target
bioactiv
databas
see
ti
oprea
issu
conceiv
one
appli
exist
inform
improv
success
rate
use
exampl
machin
learn
techniqu
develop
targetspecif
librari
includ
targetspecif
ligandspecif
inform
vol
drug
discoveri
today
technolog
silico
techniqu
box
evalu
criteria
select
molecul
chemistri
followup
chemotyp
evalu
criterion
give
higher
prioriti
chemotyp
occur
activ
compound
compar
overal
number
test
chemotyp
b
chemotyp
absent
less
present
patent
disclosur
medicin
chemistri
intellectu
properti
reason
c
chemotyp
gener
regard
safe
less
frequent
toxic
databas
chemotyp
evalu
use
rank
famili
ht
hit
appli
ii
individu
molecul
evalu
scheme
give
higher
prioriti
molecul
desir
physicochem
properti
rang
use
method
comput
eg
solubl
permeabl
b
molecul
high
er
activ
compar
less
activ
c
add
chemotyp
score
comput
earlier
final
composit
score
rank
confirm
presum
activ
wwwdrugdiscoverytodaycom
postht
analysi
process
give
higher
prioriti
highqual
probe
perhap
download
entir
matrix
targetbioact
data
use
profil
compound
